CANCERS BRONCHIQUES NON A PETITES CELLULES : CHIMIOTHERAPIE ADJUVANTE APRES RESECTION COMPLETE |
|
|
Référence |
Méthodologie |
Critère de jugement |
Nombre d'essais |
Nombre de patients |
Résultat |
|
Chimiothérapie adjuvante après chirurgie |
|||||
|
Collaborative Group, 1995 (1) |
MADI |
Survie globale |
14 |
4357 |
NS HR = 0,87 |
|
Sculier,
2001
(2) |
MARSL |
Survie globale |
6 |
1280 |
S HR = 0,85 (IC 95% 0,73 - 0,99) |
|
Hotta,
2004
(3) |
MAI |
Survie globale |
11 |
5538 |
S HR = 0,87 (IC 95% 0,80 – 0,94) |
|
Sedrakyan,
2004
(4) |
MAI |
Survie globale |
19 |
7200 |
S |
|
Berghmans,
2005
(5) |
MARSL |
Survie globale |
19 |
7764 |
S HR = 0,84 (IC 95% 0,78 – 0,89) |
|
Hamada, 2005
(6) |
MADI |
Survie à 5 et 7 ans |
8 |
2082 |
S HR = 0,74 (IC 95% 0,61 – 0,88) |
|
Pignon, 2008
(7) |
MADI |
Survie globale |
5 (LACE) |
4584 |
S HR = 0,89 (IC 95% 0,82 – 0,96) |
|
Bria, 2009
(8) |
MAI |
Survie globale |
12 |
7334 |
S |
|
Lim, 2009
(9) |
MARSL |
Survie globale |
22 |
|
S HR = 0,80 (IC 95% 0,74 – 0,87) |
|
Hamada, 2009
(10) |
MADI St IA |
Survie globale |
6 |
1269 |
T1b : S HR = 0,69 (IC 95% 0,42 – 0,90) T1a : NS HR = 0,84 (IC 95% 0,58 – 1,23) |
|
Aupérin, 2010
(11) |
MADI Sans radiothérapie |
Survie globale |
34 |
8447 |
S HR = 0,86 (IC 95% 0,81 – 0,92) |
|
Avec radiothérapie |
Survie globale |
13 |
2260 |
S HR = 0,88 (IC 95% 0,81 – 0,97) |
|
Références
(1) Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995 Oct 7;311(7010):899-909.
(2) Sculier JP, Berghmans T, Paesmans M, Branle F, Lemaitre F, Mascaux C, et al. La place de la chimiothérapie dans le traitement des cancers bronchiques non à petites cellules non métastatiques. [The role of chemotherapy in the treatment of non-metastatic, non-small cell bronchial cancers]. Rev Med Brux 2001 Dec;22(6):477-87.
(3) Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004 Oct 1;22(19):3860-7.
(4) Sedrakyan A, Van Der MJ, O'Byrne K, Prendiville J, Hill J, Treasure T. Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. J Thorac Cardiovasc Surg 2004 Sep;128(3):414-9.
(5) Berghmans T, Paesmans M, Meert AP, Mascaux C, Lothaire P, Lafitte JJ, et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005;49:13-23.
(6) Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, Imaizumi M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 2005 Aug 1;23(22):4999-5006.
(7) Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008 Jul 20;26(21):3552-9.
(8) Bria E, Gralla RJ, Raftopoulos H, Cuppone F, Milella M, Sperduti I, et al. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. Lung Cancer 2009 Jan;63(1):50-7.
(9) Lim E, Harris G, Patel A, Adachi I, Edmonds L, Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol 2009 Nov;4(11):1380-8.
(10) Hamada C, Tsuboi M, Ohta M, Fujimura S, Kodama K, Imaizumi M, et al. Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials. J Thorac Oncol 2009 Dec;4(12):1511-6.
(11) Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le CT, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010 Apr 10;375(9722):1267-77.